background: Although preimplantation genetic screening (PGS) is widely offered, there are contradictory reports on the clinical merit of this procedure. Any gain from embryo selection following aneuploidy screening must significantly outweigh the impact of the procedure. Variability of technical expertise in embryo biopsy, blastomere fixation, fluorescence in situ hybridization analysis, along with suboptimal laboratory quality control and inappropriate patient selection may impact PGS outcomes.
Introduction
Preimplantation genetic diagnosis (PGD) was first introduced in the late 1980s as an alternative to prenatal diagnosis for couples at risk of passing on a serious genetic disease to their children (Handyside et al., 1989) . A subdivision of PGD, preimplantation genetic screening (PGS), is now used extensively in in vitro fertilization (IVF) clinics to identify common aneuploidy in embryos, with the aim of improving the chances of a successful outcome for IVF couples with a poor prognosis of pregnancy (Delhanty et al., 1993) . The high rate of aneuploidy (60 -70%) identified in embryos from couples with advanced maternal age, repeated IVF failure or recurrent miscarriage is considered to be a contributing factor to implantation failure, embryonic wastage and poor pregnancy rates Wilton et al., 2002; Platteau et al., 2005; Rubio et al., 2005; Munne, 2006) .
Although PGS is widely offered, there is debate surrounding its clinical merits. Although several studies have reported an increase in implantation rates and take home baby rates following PGS (Gianaroli et al., , 2001 (Gianaroli et al., , 2005 Munne et al., 1999 Munne et al., , 2003 Munne et al., , 2006 Kuliev and Verlinsky, 2008) , others have failed to show any positive effect (Staessen et al., 2004; Platteau et al., 2005; Hardarson et al., 2008; Schoolcraft et al., 2008; Twisk et al., 2008) . Moreover, one report (Mastenbroek et al., 2007) showed that PGS can have a detrimental effect on pregnancy outcomes.
In order for PGS to benefit patients, any gain from embryo selection following aneuploidy screening must significantly outweigh the impact of the embryo biopsy procedure. Removal of one or more blastomeres from the developing embryo has the potential to reduce embryo viability . In addition, the culture conditions in which an embryo is exposed to are known to affect developmental viability (Bavister, 1995) . Therefore, embryo culture conditions have the potential to impact biopsied embryos and hence PGS success rates. Large studies investigating clinical PGS procedural variation and effect on clinical outcomes are limited.
Monash IVF operates a large clinical programme that has offered PGS as a clinical procedure since January 2000. This has provided the opportunity to perform a retrospective control-matched study of substantial size to compare patient outcomes. To the best of our knowledge, the data collected during this period represent the third largest data series to be analysed. During the study period, the only significant laboratory change involved the embryo culture media. Therefore, the effect of this alteration on clinical PGS outcomes could be determined.
Materials and Methods

Study design
This study was approved by the Monash Surgical Private Hospital Human Research Ethics Committee, approval number: 07078. A retrospective control-matched analysis was conducted on cycles from patients having IVF treatment with or without PGS at Monash IVF from January 2000 to December 2006. Outcomes from a total of 1508 fresh stimulated IVF cycles with or without PGS from 1009 couples were analysed. Stimulation protocols, embryology culture systems and embryo transfer techniques were similar for both patients during this period. All patient cycles included in this study were those that had embryos created from the patient's own oocytes. Following aneuploidy screening, only embryos which were morphologically and developmentally normal with 'no abnormality detected for the chromosomes tested' were transferred in the PGS group. Cycles in which all embryos were diagnosed as aneuploid and the patient did not have a transfer were also included in the data set.
Patient matching and grouping
Over the study period, 754 PGS cycles were performed for advanced maternal age (40 years of age), repeated IVF failure (3 IVF cycles) and/or recurrent miscarriage (.2 miscarriages). Maternal age across the three clinical groups ranged from 26 to 46, with an average of 38.0 years. All patients having PGS were fully informed and consented to the procedure.
PGS cycles were matched one to one with cycles undertaken during the same time period without PGS (no PGS). Patients were matched according to the following criteria that are listed in order of priority: date of oocyte collection; maternal age; number of previous stimulated IVF cycles and the number of fertilized (2PN) oocytes. The date of oocyte collection was matched and given priority in order to take into account the change in the culture media system. There were no other significant changes in embryology over the entire study period. During patient matching, the investigators were blinded to the outcomes of the pregnancies.
Patient cycles (PGS and no PGS) were further grouped according to maternal age (,40 or 40 years) and the number of previous stimulated IVF cycles (2 and .2 cycles). Outcomes were also grouped according to whether the date of oocyte collection (EPU) occurred prior to the change in media (1st January 
Ovarian stimulation and embryo culture
Oocyte retrievals were performed 36-38 h post-human chorionic gonadotrophin (hCG) administration (either 250 mg of recombinant [rhCG] Ovidrel (Merck Serono, Australia) or 10 000 IU of urinary [uhCG] Pregnyl (Organon, Australia)). Oocytes were fertilized using either standard insemination or intracytoplasmic sperm injection, and fertilization results were assessed 16-20 h post-insemination. Embryos were transferred between Day 2 and Day 5. Luteal support consisted of either Crinone (Merck Serono) or progesterone pessaries (Orion, Australia).
Prior to June 2004, gametes and embryos were cultured in the Quinn's Advantage culture media system (Coopers Surgical, USA). This involved utilizing the Quinn's advantage fertilization, Cleavage and Blastocyst medium supplemented with human serum albumin as per manufacturer's specifications. After June 2004, the COOK sequential culture media system (COOK Medical, Australia) was adopted. Embryos were cultured using the SIVF fertilization, cleavage and blastocyst media as specified by the manufacturer.
Embryo biopsy and fluorescence in situ hybridization
For the entire study period, the embryo biopsy procedure was performed on Day 3 after oocyte collection on embryos with 5 cells. Embryos with ,5 cells were considered unsuitable for biopsy. Prior to June 2004, embryos were biopsied using Quinn's Advantage Medium with HEPES Ca Mg Free. Dishes were placed on a warm stage (378C) until the time of the biopsy. After June 2004, COOK Embryo Biopsy Medium (COOK Medical, Australia) was used for the embryo biopsy procedure. Biopsy dishes were prepared the day before use and placed in a 378C CO 2 incubator to equilibrate. Over the study period, the embryo biopsy procedure was performed on an IX70 Olympus inverted microscope using Narashige hydraulic (Tokyo, Japan) manipulators and a 378C warm stage. A Zilos laser (Hamilton Thorne, UK) was used to ablate a hole in the zona pellucida, and a single blastomere was removed. If a nucleus was not identified following fixation and the embryo had 6 cells, a second cell was removed.
Blastomeres were fixed individually using Carnoy's fixative and hybridized with two consecutive rounds of fluorescence in situ hybridization (FISH). The first round hybridization was performed using Vysis MultiVysion PGT probe (for chromosomes X, Y, 13, 18, 21), whereas the second round of hybridization used a probe combination for chromosomes 16 and 22 (Immunodiagnostics, NSW, Australia). From February 2004, the second round probe mix was expanded to include chromosome 15. This resulted in the analysis of eight clinically significant chromosomes, which together account for more than 70% of aneuploidy seen in miscarriage (Abdelhadi et al., 2003) . All technical procedures involving embryo biopsy and PGS were rigorously monitored by quality control programmes of International Organization for Standardization (ISO 9001:2000) and National Association of Testing Authorities, Australia (NATA), resulting in reliably consistent scientist performance. The performance of all laboratory staff at Monash IVF is regularly investigated by conducting internal system audits and technical performance reviews in areas of embryo biopsy, fixation and FISH concordancy to maintain high-quality standards. These audits indicate a consistency in staff performance over time. Therefore, other than the change in culture media and the introduction of chromosome 15 into the FISH screening panel, all aspects of embryo biopsy and PGS techniques remained unchanged over this time.
Outcome measures
Outcomes were measured as 'clinical pregnancy rate' (number of viable clinical pregnancies/number of embryo transfer procedures), 'implantation rate' (number of fetal heart beats/total number of embryos transferred), 'miscarriage rate' (number of fetal heart beats lost/number of fetal heart beats) and 'live birth rate' (number of delivery events/number of embryo transfer procedures). Clinical pregnancies were defined as the presence of a viable gestational sac (with fetal heart beat) on ultrasound at 6 -7 weeks gestation.
Statistical analysis
For statistical comparisons between groups, the x 2 test, Fisher exact test, Student's t-test and Mann-Whitney U-test were used. A P-value of 0.05 was considered statistically significant.
Results
Over the study period, there were two changes made in the laboratory. The first involved the addition of chromosome 15 into the FISH screening panel and the second a change to the embryo culture media (which will be discussed in detail throughout this paper). Of the embryos screened with the additional probe for chromosome 15, 5.6% of the embryos diagnosed as 'abnormal' for the chromosomes tested were found to have errors solely involving chromosome 15. If this figure was applied back to the data prior to the introduction of the chromosome 15 probe, it could be inferred that 213 embryos out of the 3819 total 2PN embryos (5.6%) may have carried an undetected abnormality solely involving chromosome 15. As 20% of embryos proceeded to transfer for this period, this equates to 42 embryos being unknowingly transferred with an abnormality involving chromosome 15 out of the 795 embryos that were transferred in total (5.3%). By deduction, the impact of the introduction of chromosome 15 into the FISH screening panel on clinical outcomes appears to have been limited.
Overall effect of PGS
The overall clinical outcomes (PGS versus no PGS) are summarized in Table I . There was no significant difference in maternal age, the mean number of previous stimulated IVF cycles per patient or the mean number of fertilized oocytes for PGS versus no PGS. As anticipated, the PGS patients had significantly fewer embryos transferred per cycle and fewer PGS cycles proceeded to transfer. Overall, 15.6% of PGS cycles did not have a transfer compared with only 1.3% of patients with no PGS. Pregnancy and live birth rates were significantly better for the no PGS patients, although there was no difference in the implantation and miscarriage rates. A limitation of this study is that there is a difference in the day of transfer between the PGS and no PGS patient groups. Although it would be ideal to be able to factor in the transfer day when analysing the data, the majority of cycles in the no PGS group had transfer on Day 2 or 3. It has only been in recent years that these patients have moved to having transfer on Day 4 or 5. If patients with a Day 2 or 3 transfer were excluded from the data set, there would have been a very limited number of cycles to select from for matching prior to the change in culture media. This would have resulted in poorer patient matches for the other matching criteria that were deemed to be more important for this particular study.
Comparison before and after the media change Table II summarizes all patient groups and clinical outcomes according to the change in media. There was no significant difference in maternal age, the mean number of previous stimulated IVF cycles and the mean number of fertilized oocytes between the PGS and no PGS patients either before or after the media change. The PGS patients had significantly less embryos transferred per cycle, with a smaller proportion of patient's cycles proceeding to transfer. Prior to the media change, both pregnancy and live birth rates were significantly higher for no PGS patients compared with PGS patients (Table II) . Following the media change, the implantation and live birth rates increased significantly for the PGS patients. The no PGS patients showed a significant increase in the implantation rate only. Interestingly, following the change in media there was no longer a significant difference in outcomes for the PGS patients versus no PGS patients.
Comparisons examining maternal age, previous cycle number and media change
Patients were further grouped according to maternal age at the time of oocyte collection (,40 and 40 years) and the number of previous stimulated IVF cycles (2 or .2 fresh IVF cycles). For patients ,40 years (Tables III and IV) , there was no significant difference in maternal age or the mean number of fertilized oocytes between the groups. The mean number of previous stimulated IVF cycles per patient with .2 previous IVF cycles was significantly higher in the PGS group than in the no PGS controls for both periods (Table IV) . The PGS patients had significantly fewer embryos transferred per cycle with a smaller proportion of patient's cycles proceeding to transfer (Tables III and IV) .
For couples with maternal age ,40 years who had 2 previous stimulated IVF cycles, 106 PGS cycles were undertaken prior to the media change and 72 PGS cycles after the media change. Prior to the media change, the PGS patients had a significantly lower pregnancy rate, implantation rate and live birth rate (17.4, 11.3 and 16.3%, respectively) than the no PGS controls (31.4, 20.1 and 29.5%, respectively). Following the media change, the implantation rate for the PGS couples increased significantly and there was no longer any difference in clinical outcomes between PGS and no PGS couples (Table III) .
For couples with maternal age ,40 years with .2 previous stimulated IVF cycles, there were 176 PGS cycles prior to the media change and 102 PGS cycles after the media change. Both PGS and no PGS patients had improved clinical outcomes following the media change. There was no significant difference between PGS and no PGS groups either before or after the media change (Table IV) . Patients with advanced maternal age 40 years at the time of oocyte collection were grouped according to the number of previous stimulated IVF cycles (2 or .2 fresh IVF cycles; Tables V and VI). Prior to the media change, PGS patients 40 years with 2 previous stimulated IVF cycles did not have significantly different clinical outcomes compared with the no PGS controls. Following the media change, PGS outcomes improved significantly. There was no such improvement for the no PGS patients. Furthermore, following the media change, the pregnancy rate, implantation rate and live birth rate for PGS patients were significantly better than the clinical outcomes for no PGS patients (Table V) . The miscarriage rate for PGS couples showed no significant difference with regard to the media change.
For Different superscripts indicate a significant difference over the four columns (pre-and post-media change for PGS and no PGS).
cycles after the media change. PGS and no PGS patients showed no significant improvement in clinical outcomes following the media change. Furthermore, there was no significant difference between PGS and no PGS couples either before or after the media change (Table VI) .
Error rates/measurement of uncertainty
Over the study period, 91.6% of the embryos biopsied had conclusive results after PGS. Therefore, the rate of undiagnosed embryos was 1% for the Y chromosome. This is a reflection of the Vysis MultiVysion PGT probe hybridization efficiency under our laboratory conditions. For the purposes of quality assurance, 49 embryos that were identified as aneuploid using PGS were reanalysed using the same FISH probe set (chromosomes X, Y, 13, 15, 16, 18, 21 and 22) . Of these embryos, two embryos that were initially diagnosed as abnormal were found on reanalysis to be normal for the chromosomes tested. Therefore, the false-positive rate was 4.1%. This is lower than the false-positive rates published by other authors, however the number of embryos reanalysed was small (Abdelhadi et al., 2003: 10.6%; Gianaroli et al., 1999: 5%; Munne et al., 1999: 7-15%; Munne et al., 2003: 12% and Staessen et al., 2004: 8.4% ).
Discussion
Since the advent of embryo biopsy and the application of FISH procedures to interpret chromosome aneuploidy in single blastomeres, the methodology has been continuously evaluated in an endeavour to minimize the detrimental effect on the embryo and optimize the outcomes for patients (Cohen and Grifo, 2007) . As far as we are aware, this control-matched data series is the third largest reported cohort of PGS patients. Despite the recent publication of a number of randomized control trials (RCTs) (Mastenbroek et al., 2007; Hardarson et al., 2008; Schoolcraft et al., 2008; Twisk et al., 2008) , the controversy surrounding the clinical merits of PGS is still ongoing. Although RCTs are less likely to be affected by bias, their external validity is not necessarily guaranteed as laboratory procedures vary widely. This data analysis suggests justification for the varying outcomes different clinics have reported.
Our results show that when looking at the two patient populations as a whole (PGS versus no PGS), clinical outcomes were better for the no PGS patients. Prima facie, this confirms previously reported findings that PGS does not offer a clinical benefit (Staessen et al., 2004; Platteau et al., 2005; Mastenbroek et al., 2007; Hardarson et al., 2008; Schoolcraft et al., 2008; Twisk et al., 2008) . However, when the data were further analysed with respect to a major event that impacted the embryo biopsy and culture system, the results were different. Prior to the media change, the no PGS patients seemed to have better clinical outcomes. However, following the media change there was no longer a difference between the PGS and no PGS patients (Table II) . These results clearly demonstrate that a change in embryo biopsy and culture system can cause a significant variation in clinical outcome. Interestingly, our data suggest that the improved culture conditions are of greater benefit to biopsied embryos. It could be speculated that non-biopsied embryos are already near their full potential and better culture conditions may not result in significant improvements, whereas the 'injury' of the biopsy may be overcome with the improved media. Differences in media constitution may account for this. The media used for the first part of the study (Quinn's Advantage, Sage) was relatively non-complex and nonsequential, whereas the current media (COOK) is more complex and sequential. It contains various components designed to help the embryo osmoregulate (glycine and taurine) and maintain homeostasis (amino acids, glutamate, pyruvate, lactate and glucose). Potentially these compounds could mitigate some of the metabolic stress (such as no calcium and magnesium being present in the biopsy medium) and possible damage (physically removing blastomeres) that occurs during embryo biopsy. These results support the views given by other authors that it is crucial for laboratories offering PGS to have extensive expertise, particularly in the areas of patient selection, embryo biopsy, blastomere fixation and FISH analysis (Shahine and Cedars, 2006; Munne et al., 2007a, b; Harper et al., 2008) . Given this, PGS may not be detrimental in experienced hands. The results from this study clearly demonstrate that it is important for each group to analyse their own data to determine whether their culture system has been optimized to the level required for PGS. When factoring in the maternal age, the number of previous stimulated IVF cycles and the change in media, significant differences in clinical outcomes emerge between the patient groups. For patients 40 years with 2 previous stimulated IVF cycles, there was no difference in clinical outcomes between the PGS and no PGS patients prior to the media change (Table V) . However, following the media change, clinical outcomes significantly improved for PGS patients. No similar improvement was seen for the no PGS patients. Taken together, these results indicate that couples with maternal age 40 years with 2 previous stimulated IVF cycles are most likely to benefit from PGS, supporting previously published findings (Gianaroli et al., , 2005 Munne et al., 1999 Munne et al., , 2003 Rubio et al., 2005) . Our results are comparable to those reported by Munne et al. (2003) in a similar control-matched study. They demonstrated that women of advanced maternal age (35 years) who undertook PGS had increased implantation rates (18%) compared with no PGS controls (11%). They further subdivided this group according to the number of previous stimulated IVF cycles and the number of fertilized oocytes. They found that patients with 2 previous stimulated IVF cycles and 8 embryos had the most significant improvement in the implantation rate following PGS (19.2% compared with 8.8% in no PGS controls).
The patient group found least likely to demonstrate a benefit from having PGS was the group of women with maternal age ,40 years and particularly patients who have undertaken a small number of stimulated IVF cycles. These results also confirm the published findings of Munne et al. (2003) . PGS is expected to have a lesser impact on clinical outcomes in this patient group in view of the increasing incidence of aneuploidy with maternal age (Platteau et al., 2005) . Also, in this patient group (,40 years with 2 previous stimulated IVF cycles), the comparison between PGS and no PGS patients is flawed. Compared with the no PGS group, the younger PGS couples are generally a historically compromised patient set (i.e. suffering recurrent miscarriage prior to IVF) and are having PGS to improve their chance of a successful pregnancy. Patients with recurrent IVF failure may have other contributing factors leading to the infertility (Kahraman et al., 2000) , and those with small numbers of embryos are less likely to benefit from the added embryo selection following PGS . The fact that there is no difference in clinical outcomes for PGS versus no PGS patients following the change in media is encouraging and indicates that the embryo biopsy procedure is not harming the embryo's ability to implant or to result in the birth of a healthy child. Furthermore, although clinical outcomes were not improved for the PGS patients in these groups, it could be argued that PGS has still potentially provided a benefit by reducing the risk of down syndrome and other chromosomal abnormalities at birth.
In the current study, there was no statistical difference in miscarriage rates for all patient groups. However, there appeared to be a trend that the miscarriage rate was reduced for PGS patients after the change in media. Presumably these results are not significant given the small numbers in each patient group. A small RCT by Schoolcraft et al. (2008) has shown a similar trend with no significant difference in the spontaneous miscarriage rate for the PGS group (25.9%) compared with the control group (32.3%).
PGS patients were less likely to proceed to transfer than the no PGS patients. This was due to the fact that a number of PGS cycles had all embryos diagnosed as aneuploid, and therefore had no embryos available for transfer. By having PGS, these patients have avoided the stress, trauma and worry involved in having a transfer that would not have achieved a healthy pregnancy Munne et al., 1999; Wilton et al., 2002) .
A recent multicentre, double blind RCT by Mastenbroek et al. (2007) has fuelled the debate on the efficiency of PGS. They compared three cycles of IVF from patients with and without PGS and have indicated a detrimental effect of the screening on clinical pregnancy rate, ongoing pregnancy rate and live birth rate in 408 women with advanced maternal age (35-41 years). The ongoing pregnancy rate was significantly lower in the PGS group (24%) compared with the control group (37%). These findings have since been challenged for a variety of reasons, including a lack of technical experience, suboptimal laboratory practice, inappropriate selection of patients, the absence of screening for clinically significant chromosomes (15 and 22) and an increased rate of test/technical failure (20.1%) (Braude and Flinter, 2007; Cohen and Grifo, 2007; Munne et al., 2007a, b; Kuliev and Verlinsky, 2008) . In response, the same centre reassessed the data to see whether the effect of PGS on live birth rates varied for different subgroups of patients, in particular advanced maternal age patients with an increased risk for aneuploidy (Twisk et al., 2008) . The subgroups analysed were maternal age (,38 or 38), the number of previous miscarriages (0, 1, 2 and .2), semen quality, recombinant FSH and the number of high-quality embryos. Overall analysis showed that live birth rates were significantly lower for PGS patients. Further analysis demonstrated that although live birth rates were greater in the majority of subgroups of control patients, the difference was not significant. Hardarson et al. (2008) recently reported findings from another two-centre RCT investigating whether PGS would increase the clinical pregnancy rate in women 38 years of age. Due to a slow recruitment rate, they performed an interim analysis of the data after 109 patients were treated. Analysis of outcomes showed that there was no significant difference in the pregnancy rate per embryo transfer (PGS 22.2% and control 30.2%), implantation rate (PGS 11.4% and control 18.9%) and miscarriage rate (PGS 70% and control 37.5%) between the PGS and control groups. However, the live birth rate per patient was significantly lower for the PGS group 5.4% compared with 18.9% for the control group. The results of the interim analysis prompted the researchers to prematurely halt recruitment. It is of concern, however, that there is such a drop-off in the live birth rate compared with the implantation rate in the PGS group. Even in the study by Mastenbroek et al. (2007) such a drop-off from the implantation rate was not seen.
A prospective RCT published by Schoolcraft et al. (2008) has also shown that PGS failed to significantly improve cycle outcomes in 62 infertile patients aged 35 years. Although a relatively small study, their results showed comparable implantation rates with PGS (36.5%) or without PGS (37.3%), and the authors concluded that these comparable results support that the embryo biopsy procedure does not have a detrimental effect. Other groups have performed similar studies on PGS patients. Gianaroli et al. (1999) set out to identify the advantages gained from PGS in patients with poor prognosis of pregnancy using a randomized controlled study. They found that PGS had a positive impact on implantation rate, particularly in patients 38 years or older (22.5% in PGS patients compared with 10.2% in control patients). A more recent study involving couples with advanced maternal age 37 years compared the outcomes of patients who had undertaken PGS for seven chromosomes to the control group who had undertaken a similar number of cycles without PGS (Staessen et al., 2004) . The implantation rate after PGS was 17.1% compared with 11.5% for the control group, with a live birth rate of 16.5 and 10.4%, respectively, but the results were not significantly different (Staessen et al., 2004) . It must be noted that there are huge variations in the definition of advanced maternal age within the literature, with as much as a 5-year variation between publications, which make comparisons and conclusions difficult.
The results of this study suggest that PGS laboratory procedures can significantly impact clinical outcomes and may bias interpretation of the overall benefit of the PGS procedure. Although each group's published findings may be indicative of PGS outcomes in their clinic, they may not be truly indicative of the potential of PGS to improve patient outcomes. Given the impact this laboratory change has made on our success rates, data analysis from other laboratories should take into consideration any major changes that have taken place during their study period. In addition, it is quite conceivable that outcomes for the published RCTs may have been more favourable towards PGS had similar culture techniques been used. We are currently planning an RCT to confirm the improved clinical outcomes seen in our PGS patients, in particular the subgroup with advanced maternal age 40 and with 2 previous stimulated IVF cycles.
